Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.
The financing will support growth in Maravai's three life science segments: bioprocess impurity testing, oligonucleotide synthesis, and protein detection.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Scientists led by Eric Kmiec showed that their strategy of point mutation editing with single-stranded DNA oligos and double-strand breaks works with CRISPR/Cas9.
Single nucleus sequencing analysis of triple-negative breast tumors indicated that copy number changes occur in bursts early in tumor evolution.
In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.